1153 related articles for article (PubMed ID: 29275462)
1. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
2. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
4. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Gajewski TF
Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
[TBL] [Abstract][Full Text] [Related]
5. The STING pathway and the T cell-inflamed tumor microenvironment.
Woo SR; Corrales L; Gajewski TF
Trends Immunol; 2015 Apr; 36(4):250-6. PubMed ID: 25758021
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Spranger S
Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
[TBL] [Abstract][Full Text] [Related]
7. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
8. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
9. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Trujillo JA; Sweis RF; Bao R; Luke JJ
Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
[TBL] [Abstract][Full Text] [Related]
10. Innate and adaptive immune cells in the tumor microenvironment.
Gajewski TF; Schreiber H; Fu YX
Nat Immunol; 2013 Oct; 14(10):1014-22. PubMed ID: 24048123
[TBL] [Abstract][Full Text] [Related]
11. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Spranger S; Luke JJ; Bao R; Zha Y; Hernandez KM; Li Y; Gajewski AP; Andrade J; Gajewski TF
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7759-E7768. PubMed ID: 27837020
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
13. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
14. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
15. Cellular immune responses towards regulatory cells.
Larsen SK
Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
[TBL] [Abstract][Full Text] [Related]
16. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Spranger S; Bao R; Gajewski TF
Nature; 2015 Jul; 523(7559):231-5. PubMed ID: 25970248
[TBL] [Abstract][Full Text] [Related]
17. Innate immune signaling and regulation in cancer immunotherapy.
Corrales L; Matson V; Flood B; Spranger S; Gajewski TF
Cell Res; 2017 Jan; 27(1):96-108. PubMed ID: 27981969
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
19. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Sweis RF; Spranger S; Bao R; Paner GP; Stadler WM; Steinberg G; Gajewski TF
Cancer Immunol Res; 2016 Jul; 4(7):563-8. PubMed ID: 27197067
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
